Mice Model Market

Mice Model Market by Model Types & Services (Inbred Mice, Genetically Engineered Mice), Technology (Microinjection, Nuclear Transfer, CRISPR/CAS9), Application (PDx Models, Drug Discovery), End User (Pharma, Biotech, CROs, CDMOs) - Global Forecast to 2028

Report Code: BT 2192 Apr, 2023, by marketsandmarkets.com

Updated on : May 04, 2023

The global mice model market in terms of revenue was estimated to be worth $1.4 billion in 2023 and is poised to reach $2.7 billion by 2028, growing at a CAGR of 13.9% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The key factors driving the growth of the market are rise in the investment and advancements in the mouse model technology, increasing implications of mouse clinical trials (MCTs) for more predictive outcomes, and increasing demand for personalized medicine. However, in December 2022, the U.S.FDA announcement of no longer requiring all drugs to be tested on animals before human trials and development of alternative animal testing methods is causing hurdles in the market.

Attractive Opportunities in the Mice Model Market

Mice Model Market

To know about the assumptions considered for the study, Request for Free Sample Report

Mice Model Market

Mice model Market Dynamics

DRIVER: Rising investments in mouse model-based research

Rising investments in research & development for the mouse model market is a crucial factor driving the market growth. In recent years, the R&D expenditure in the US has increased exponentially. The United States (US) medical & health research and development (R&D) investment reached $245.1 billion in 2020, an 11.1% increase from 2019. According to the EU, in 2022, the total R&D investment from the top 2500 companies worldwide was EUR 1093.9 billion, an amount equivalent to 86% of the world’s business funded R&D. Over 60% of NIH extramural funding involves animal models, and approximately 80% to 90% of these are mouse models of human disease (Source: Oxford University Press). The increasing funding for these research processes can also be credited to the rising support from government organizations and biopharmaceutical companies worldwide for research projects related to humanized and knockout mice models. For instance, in April 2022, the Medical Research Council (MRC) launched the National Mouse Genetics Network, which marked a significant Euro 22 million investment in mouse genetics for modelling human disease (Source: UK Research and Innovation). This Network established the focus on mouse genetics for disease modeling which is expected to improve diagnosis & treatment by driving the integration of mouse genetics, cell and tissue systems, and deep phenotyping with human or clinical genomics and pathology.

RESTRAINT: Introduction of 3D-printed mouse models

In recent years, there has been a rise in the demand for 3D-printed mouse models, which are used as an alternative to traditional mouse models. These models are also cost-affordable as compared to humanized mouse models. For instance, in February 2023, research was conducted for an inexpensive 3D-printed mouse model for treating Distraction Osteogenesis (DO). This innovation created a new opportunity for 3D printing applications in the mouse model market. This research has provided reproducible and reliable osteogenesis and holds great promise to accelerate research and improve clinical outcomes for patients undergoing long bone DO. (Source: National Center of Biotechnology Information). 3D printing has also significantly impacted the quality, efficiency, and reproducibility of preclinical magnetic resonance imaging. It has vastly expanded the ability to produce MR-compatible parts that readily permit customization of animal handling, promptly achieve consistent positioning of anatomy and RF coils, and accelerate throughput. It enables the rapid and cost-effective creation of parts customized to a specific imaging study, animal species, animal weight, or even one unique animal not routinely used in preclinical research.

OPPORTUNITY: Utilization of CRISPR in biomedical research

CRISPR is now a revolutionary technology for gene editing. Using the Cas9 enzyme differentiates CRISPR from other forms of genetic modification. This technology edits and rearranges genes by cutting out damaged or unwanted parts of the DNA, allowing the remaining DNA to be rearranged in a new way. This fast, precise, and easy-to-use technology is considered a revolutionary tool in research, and there is intense interest in validating its therapeutic usage in humans. CRISPR was used to work in mouse and human cells and has already been applied to various biological systems and disease areas. The clustered, regularly interspaced short palindromic repeats (CRISPR) system, derived from the adaptive immune system of prokaryotes, is a breakthrough genome editing technology that can be applied to various research. CRISPR is used in the development of genetically modified mice strains, making the process not only quicker but also less expensive.

CHALLENGE: Development of alternative animal testing methods

The rapid growth in efficient and reliable alternatives to animal testing poses a challenge for the market. Moreover, increasing pressure from animal rights activists has forced research institutes and companies to seek options to minimize the use of testing in research.

Mice Model Market Ecosystem

Prominent companies in the market include well established, financially stable manufacturers of mice models and services. These companies have been operating in the market for several years and posees diversified product portfolio, state-of-the-art technologies, and strong global sales and marketing networks. Prominent companies in this market include Charles River Laboratories (US), The Jackson Laboratory (US), Inotiv (US), genOway (France), and Taconic Biosciences, Inc. (US).

Mice Model Market Ecosystem

The model types accounted for the largest share of the model types & services segment in mice model market in 2022.

Based on model types & services, the market is categorized into model types, and services. In 2022, the model types segment accounted for the largest share of the market. The availability of various types of mice models due to advancements in biotechnology is further driving the usage of mice as animal models for research activities.

The CRISPR segment dominated the technology segment in mice model market in 2022.

Based on the technology, the segment is categorized into CRISPR/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies. In 2022, the CRISPR segment dominated the technology segment with the highest revenue share. Advantages of CRISPR are likely to drive the market growth.

North America was the largest market for mice model market in 2022.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and MEA. The market is dominated by North America in 2022 and this dominance is anticipated to continue throughout the forecast period. The increasing incidence of cancer and infectious diseases and the demand for improved resources (cell lines and animals like mice) in order to improve production efficiency and deliver greater yields of antibodies are expected to drive the market. However, the recent bills promoting the use of alternative technologies for animal testing are negatively impacting the market growth.

Mice Model Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the mice model market are Charles River Laboratories (US), The Jackson Laboratory (US), Inotiv (US), genOway (France), Taconic Biosciences, Inc. (US), Janvier Labs (France), Harbour BioMed (China), Trans Genic Inc. (Japan), Ingenious Targeting Laboratory (US), PolyGene AG (Switzerland), Aragen Life Sciences Ltd. (India), Cyagen Biosciences (US), Crown Biosciences (US), TransCure bioServices (France), Ozgene Pty. Ltd. (Australia), The Andersons, Inc. (US), Allentown, LLC (US), Innovive (US), Lab Products, LLC. (US), Crescendo Biologics Limited (UK), ImmunoGenes (Hungary), Lexicon Pharmaceuticals, Inc. (US), Horizon Discovery Ltd (UK). Marshall BioResources (US), and Applied StemCell Inc. (US).

Mice Model Market Report Scope

Report Metric

Details

Market Revenue in 2023

$1.4 billion

Projected Revenue by 2028

$2.7 billion

Revenue Rate

Poised to grow at a CAGR of 13.9%

Market Driver

Rising investments in mouse model-based research

Market Opportunity

Utilization of CRISPR in biomedical research

This report categorizes the mice model market to forecast revenue and analyze trends in each of the following submarkets:

By Model Types & Services

  • Model Types
    • Inbred Mice
    • Genetically Engineered Mice
    • Outbred Mice
    • Hybrid/Congenic Mice
  • Services
    • Breeding
    • Cryopreservation
    • Rederivation
    • Quarantine
    • Other Services

By Technology

  • CRISPR/CAS9
  • Microinjection
  • Embryonic Stem cell Injection
  • Nuclear Transfer
  • Other Technologies

By Application

  • Drug Discovery & Development
  • Basic Research
  • PDx Models/Xenografts

By End User

  • Academic Institutes & Research Centers
  • Pharma & Biotech Companies
  • CROs & CDMOs

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • Japan
    • India
    • China
    • Australia
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
  • Middle East and Africa

Recent Developments

  • In April 2019, Charles River acquired Citoxlab to strengthen its portfolio & geographic footprint, enhancing the ability to partner with clients across the drug discovery and development continuum. This acquisition helped Charles River strengthen its position in regulated safety assessment services, non-regulated discovery services, animal research models, and medical device testing.
  • In June 2020, Charles River Laboratories established two new offices in China and Singapore, combined with its existing locations in Japan, Taiwan, India, and South Korea. These offices support sales and project management for biologics research.
  • In January 2022, Inotiv completed the acquisition of Orient BioResource Center, Inc. from Orient Bio, Inc., a preclinical CRO and animal model supplier based in Seongnam, South Korea. Orient BioResource Center is a primate quarantine & holding facility located near Alice, Texas.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 37)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 STUDY SCOPE 
    1.4 YEARS CONSIDERED 
    1.5 CURRENCY CONSIDERED 
    1.6 RESEARCH LIMITATIONS 
    1.7 STAKEHOLDERS 
           1.7.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 40)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 MICE MODEL MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET ESTIMATION METHODOLOGY 
          FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
          FIGURE 4 MARKET SIZE (USD MILLION)
          FIGURE 5 MARKET: FINAL CAGR PROJECTION (2023−2028)
          FIGURE 6 MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.3 MARKET DATA ESTIMATION AND TRIANGULATION 
           2.3.1 DATA TRIANGULATION
                    FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.4 INDUSTRY INSIGHTS 
    2.5 STUDY ASSUMPTIONS 
    2.6 RECESSION IMPACT: MARKET 
          TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2023–2028 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 50)
    FIGURE 8 MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2023 VS. 2028 (USD MILLION)
    FIGURE 9 MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET: GEOGRAPHICAL SNAPSHOT
 
4 PREMIUM INSIGHTS (Page No. - 53)
    4.1 MICE MODEL MARKET OVERVIEW 
          FIGURE 12 INCREASING DEMAND FOR MOUSE-BASED CLINICAL TRIALS TO DRIVE MARKET
    4.2 NORTH AMERICA: MARKET, BY MODEL TYPE AND SERVICE (2022) 
          FIGURE 13 MICE MODELS SEGMENT IN THE US ACCOUNTED FOR LARGEST MARKET SHARE
    4.3 MARKET SHARE, BY END USER, 2023 VS. 2028 
          FIGURE 14 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 15 CHINA TO REGISTER HIGHEST GROWTH RATE IN ASIA PACIFIC MARKET DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 56)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 16 MICE MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 4 MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Rising investments in mouse model-based research
                    5.2.1.2 Increasing demand for mouse-based clinical trials (MCTs)
                    5.2.1.3 Growing preference for personalized medicine
           5.2.2 RESTRAINTS
                    5.2.2.1 Introduction of 3D-printed mouse models
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Utilization of CRISPR in biomedical research
           5.2.4 CHALLENGES
                    5.2.4.1 Development of alternative animal testing methods
    5.3 TECHNOLOGY ANALYSIS 
    5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 17 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
    5.5 SUPPLY AND VALUE CHAIN ANALYSIS 
           5.5.1 MARKET: SUPPLY CHAIN ANALYSIS
                    FIGURE 18 MARKET: SUPPLY CHAIN MAP
           5.5.2 MARKET: VALUE CHAIN MAP
                    FIGURE 19 MARKET: VALUE CHAIN MODEL
    5.6 ECOSYSTEM ANALYSIS 
          FIGURE 20 MARKET: ECOSYSTEM MAP
    5.7 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 5 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.7.1 THREAT OF NEW ENTRANTS
           5.7.2 THREAT OF SUBSTITUTES
           5.7.3 BARGAINING POWER OF BUYERS
           5.7.4 BARGAINING POWER OF SUPPLIERS
           5.7.5 INTENSITY OF COMPETITIVE RIVALRY
    5.8 REGULATORY ANALYSIS 
           5.8.1 INTRODUCTION
           5.8.2 NORTH AMERICA
           5.8.3 EUROPE
           5.8.4 CHINA
           5.8.5 JAPAN
           5.8.6 INDIA
           5.8.7 AUSTRALIA
           5.8.8 BRAZIL
    5.9 PATENT ANALYSIS 
          FIGURE 21 MARKET: PATENT FILING TRENDS (2010-2022)
    5.10 PRICING ANALYSIS 
          TABLE 6 AVERAGE SELLING PRICE OF PRODUCTS BY MANUFACTURERS
           5.10.1 MARKET: AVERAGE SELLING PRICE TREND ANALYSIS
    5.11 KEY CONFERENCES 
           5.11.1 MARKET: KEY CONFERENCES (2023)
                     TABLE 7 MARKET: KEY CONFERENCES (2023)
    5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 22 MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
           5.12.2 MARKET: KEY BUYING CRITERIA
                     FIGURE 23 KEY BUYING CRITERIA FOR END USERS
 
6 MICE MODEL MARKET, BY MODEL TYPE AND SERVICE (Page No. - 74)
    6.1 INTRODUCTION 
          TABLE 8 MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
    6.2 MODEL TYPE 
           6.2.1 INTRODUCTION
                    TABLE 9 MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
           6.2.2 INBRED MICE MODEL
                    6.2.2.1 Growing applications of inbred mice in mAb production and pharmacology to drive market
                                TABLE 10 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 11 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 12 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 13 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.3 OUTBRED MICE MODEL
                    6.2.3.1 Genetic diversity offered by outbred mice to drive market
                                TABLE 14 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 15 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 16 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 17 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.4 GENETICALLY ENGINEERED MICE MODEL
                    6.2.4.1 Increasing focus on personalized medicine for cancer and CVD to drive segment growth
                                TABLE 18 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 19 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 20 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 21 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.5 HYBRID/CONGENIC MICE MODEL
                    6.2.5.1 Increasing demand for congenic mice in biomedical research to drive market
                                TABLE 22 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 23 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 24 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 25 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 SERVICES 
           6.3.1 INTRODUCTION
                    TABLE 26 MICE MODEL MARKET, BY SERVICES, 2021–2028 (USD MILLION)
           6.3.2 BREEDING SERVICES
                    6.3.2.1 Growing number of mice model studies to fuel market
                                TABLE 27 MARKET FOR BREEDING SERVICES, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 28 NORTH AMERICA: MARKET FOR BREEDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 29 EUROPE: MARKET FOR BREEDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 30 ASIA PACIFIC: MARKET FOR BREEDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.3 CRYOPRESERVATION SERVICES
                    6.3.3.1 Rising need for preservation of novel mice models to drive market
                                TABLE 31 MARKET FOR CRYOPRESERVATION SERVICES, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 32 NORTH AMERICA: MARKET FOR CRYOPRESERVATION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 33 EUROPE: MARKET FOR CRYOPRESERVATION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 34 ASIA PACIFIC: MARKET FOR CRYOPRESERVATION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.4 REDERIVATION SERVICES
                    6.3.4.1 Stringent quality assurance standards to drive market
                                TABLE 35 MARKET FOR REDERIVATION SERVICES, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 36 NORTH AMERICA: MARKET FOR REDERIVATION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 37 EUROPE: MARKET FOR REDERIVATION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 38 ASIA PACIFIC: MARKET FOR REDERIVATION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.5 QUARANTINE SERVICES
                    6.3.5.1 Rising demand for germ-free mice in histopathology and serology applications to drive market
                                TABLE 39 MARKET FOR QUARANTINE SERVICES, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 40 NORTH AMERICA: MARKET FOR QUARANTINE SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 41 EUROPE: MARKET FOR QUARANTINE SERVICE, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 42 ASIA PACIFIC: MARKET FOR QUARANTINE SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.6 OTHER SERVICES
                    TABLE 43 MARKET FOR OTHER SERVICES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 44 NORTH AMERICA: MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 45 EUROPE: MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 46 ASIA PACIFIC: MICE MOD
7 MICE MODEL MARKET, BY APPLICATION (Page No. - 93)EL MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
    7.1 INTRODUCTION 
          TABLE 47 MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    7.2 DRUG DISCOVERY & DEVELOPMENT 
           7.2.1 RISING NUMBER OF CLINICAL TRIALS TO DRIVE DEMAND FOR MICE MODELS
                    TABLE 48 MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 49 NORTH AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 50 EUROPE: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 51 ASIA PACIFIC: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 BASIC RESEARCH 
           7.3.1 INCREASING FUNDS FOR CANCER RESEARCH ON MICE MODELS TO SUPPORT MARKET GROWTH
                    TABLE 52 MARKET FOR BASIC RESEARCH, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 53 NORTH AMERICA: MARKET MODEL MARKET FOR BASIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 54 EUROPE: MARKET FOR BASIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 55 ASIA PACIFIC: MARKET FOR BASIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 PDX MODELS/ XENOGRAFTS 
           7.4.1 GROWING PREFERENCE FOR PERSONALIZED MEDICINE IN IMMUNODEFICIENT MICE MODELS TO DRIVE MARKET
                    TABLE 56 MARKET FOR PDX MODELS/XENOGRAFTS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 57 NORTH AMERICA: MARKET FOR PDX MODELS/XENOGRAFTS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 58 EUROPE: MARKET FOR PDX MODELS/XENOGRAFTS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 59 ASIA PACIFIC: MARKET FOR PDX MODELS/XENOGRAFTS, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 MICE MODEL MARKET, BY TECHNOLOGY (Page No. - 101)
    8.1 INTRODUCTION 
          TABLE 60 MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    8.2 CRISPR/CAS9 
           8.2.1 HIGH EFFICIENCY AND COST-EFFECTIVE BENEFITS TO DRIVE DEMAND FOR CRISPR-CUSTOMIZED MODELS
                    TABLE 61 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 62 NORTH AMERICA: MARKET FOR CRISPR/CAS9, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 63 EUROPE: MARKET FOR CRISPR/CAS9 TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 64 ASIA PACIFIC: MARKET FOR CRISPR/CAS9, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 MICROINJECTION 
           8.3.1 WIDELY UTILIZED TECHNIQUE FOR DEVELOPMENT OF TRANSGENIC MICE MODELS TO DRIVE MARKET
                    TABLE 65 NORTH AMERICA: MARKET FOR MICROINJECTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 66 EUROPE: MARKET FOR MICROINJECTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 67 ASIA PACIFIC: MARKET FOR MICROINJECTION, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 EMBRYONIC STEM CELL INJECTION 
           8.4.1 GROWING DEMAND FOR TARGETED MICE MODELS TO DRIVE MARKET
                    TABLE 68 NORTH AMERICA: MARKET FOR EMBRYONIC STEM CELL INJECTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 69 EUROPE: MARKET FOR EMBRYONIC STEM CELL INJECTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 70 ASIA PACIFIC: MARKET FOR EMBRYONIC STEM CELL INJECTION, BY COUNTRY, 2021–2028 (USD MILLION)
    8.5 NUCLEAR TRANSFER 
           8.5.1 POTENTIAL TO PRODUCE IDENTICAL MICE TO DRIVE MARKET
                    TABLE 71 NORTH AMERICA: MARKET FOR NUCLEAR TRANSFER, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 72 EUROPE: MARKET FOR NUCLEAR TRANSFER, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 73 ASIA PACIFIC: MARKET FOR NUCLEAR TRANSFER, BY COUNTRY, 2021–2028 (USD MILLION)
    8.6 OTHER TECHNOLOGIES 
          TABLE 74 NORTH AMERICA: MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 75 EUROPE: MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 76 ASIA PACIFIC: MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 MICE MODEL MARKET, BY END USER (Page No. - 111)
    9.1 INTRODUCTION 
          TABLE 77 MARKET, BY END USER, 2021–2028 (USD MILLION)
    9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
           9.2.1 EXTENSIVE USE OF MICE MODELS IN CANCER THERAPEUTICS TO DRIVE MARKET
                    TABLE 78 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 79 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 80 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 81 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS 
           9.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES TO DRIVE MARKET
                    TABLE 82 MARKET FOR CROS AND CDMOS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 83 NORTH AMERICA: MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 84 EUROPE: MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 85 ASIA PACIFIC: MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 ACADEMIC & RESEARCH INSTITUTES 
           9.4.1 INCREASE IN GOVERNMENT LIFE SCIENCES R&D EXPENDITURE TO DRIVE MARKET
                    TABLE 86 MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 87 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 88 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 89 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 MICE MODEL MARKET, BY REGION (Page No. - 119)
     10.1 INTRODUCTION 
             FIGURE 24 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
             TABLE 90 MARKET, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 25 NORTH AMERICA: MICE MODEL MARKET SNAPSHOT
             TABLE 91 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 92 NORTH AMERICA: MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
             TABLE 93 NORTH AMERICA: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
             TABLE 94 NORTH AMERICA: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
             TABLE 95 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 96 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 97 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Rising production of monoclonal antibodies to fuel market for mice models
                                      TABLE 98 US: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 99 US: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 100 US: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 101 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 102 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 103 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Rising activities in stem cell research to drive adoption of mice models
                                      TABLE 104 CANADA: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 105 CANADA: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 106 CANADA: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 107 CANADA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 108 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 109 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 NORTH AMERICA: RECESSION IMPACT
     10.3 EUROPE 
             TABLE 110 EUROPE: MICE MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 111 EUROPE: MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
             TABLE 112 EUROPE: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
             TABLE 113 EUROPE: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
             TABLE 114 EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 115 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 116 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Rising research activities in biotechnology industry to drive market
                                      TABLE 117 GERMANY: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 118 GERMANY: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 119 GERMANY: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 120 GERMANY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 121 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 122 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.2 FRANCE
                        10.3.2.1 Rising research in proteomics & genomics to drive adoption of genetically engineered mice models
                                      TABLE 123 FRANCE: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 124 FRANCE: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 125 FRANCE: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 126 FRANCE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 127 FRANCE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 128 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Increasing focus on cancer research to drive market
                                      TABLE 129 UK: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 130 UK: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 131 UK: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 132 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 133 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 134 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Rising demand for preclinical research in pharmaceutical & biotechnology industry to support market growth
                                      TABLE 135 ITALY: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 136 ITALY: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 137 ITALY: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 138 ITALY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 139 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 140 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 High number of pharmaceutical laboratories to fuel market for mice models
                                      TABLE 141 SPAIN: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 142 SPAIN: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 143 SPAIN: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 144 SPAIN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 145 SPAIN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 146 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 REST OF EUROPE
                        TABLE 147 REST OF EUROPE: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                        TABLE 148 REST OF EUROPE: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                        TABLE 149 REST OF EUROPE: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                        TABLE 150 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 151 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 152 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.7 EUROPE: RECESSION IMPACT
     10.4 ASIA PACIFIC 
             FIGURE 26 ASIA PACIFIC: MICE MODEL MARKET SNAPSHOT
             TABLE 153 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 154 ASIA PACIFIC: MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
             TABLE 155 ASIA PACIFIC: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
             TABLE 156 ASIA PACIFIC: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
             TABLE 157 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 158 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 159 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.1 JAPAN
                        10.4.1.1 Increasing focus on advancements in mice model technologies to drive market
                                      TABLE 160 JAPAN: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 161 JAPAN: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 162 JAPAN: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 163 JAPAN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 164 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 165 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 International alliances for R&D activities to drive adoption of mice models
                                      TABLE 166 CHINA: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 167 CHINA: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 168 CHINA: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 169 CHINA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 170 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 171 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Rising initiatives in drug discovery development to fuel uptake of inbred mice
                                      TABLE 172 INDIA: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 173 INDIA: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 174 INDIA: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 175 INDIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 176 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 177 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 SOUTH KOREA
                        10.4.4.1 Rising R&D investments in drug development to fuel uptake for genetically engineered mice models
                                      TABLE 178 SOUTH KOREA: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 179 SOUTH KOREA: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 180 SOUTH KOREA: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 181 SOUTH KOREA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 182 SOUTH KOREA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 183 SOUTH KOREA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.5 AUSTRALIA
                        10.4.5.1 High number of research institutes to drive market for mouse-based clinical trials
                                      TABLE 184 AUSTRALIA: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 185 AUSTRALIA: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 186 AUSTRALIA: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 187 AUSTRALIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 188 AUSTRALIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 189 AUSTRALIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.6 REST OF ASIA PACIFIC
                        TABLE 190 REST OF ASIA PACIFIC: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                        TABLE 191 REST OF ASIA PACIFIC: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                        TABLE 192 REST OF ASIA PACIFIC: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                        TABLE 193 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 194 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 195 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.7 ASIA PACIFIC: RECESSION IMPACT
     10.5 LATIN AMERICA 
             10.5.1 GROWING PHARMACEUTICAL INDUSTRY AND DRUG DEVELOPMENT ACTIVITIES TO SUPPORT MARKET GROWTH
                        TABLE 196 LATIN AMERICA: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                        TABLE 197 LATIN AMERICA: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                        TABLE 198 LATIN AMERICA: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                        TABLE 199 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 200 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 201 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.2 LATIN AMERICA: RECESSION IMPACT
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 RISING EXPANSION OF PHARMACEUTICAL FACTORIES TO SUPPORT MARKET GROWTH
                        TABLE 202 MIDDLE EAST & AFRICA: MICE MODEL MARKET, BY MODEL TYPE AND SERVICE, 2021–2028 (USD MILLION)
                        TABLE 203 MIDDLE EAST & AFRICA: MARKET, BY MODEL TYPE, 2021–2028 (USD MILLION)
                        TABLE 204 MIDDLE EAST & AFRICA: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                        TABLE 205 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 206 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 207 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
 
11 COMPETITIVE LANDSCAPE (Page No. - 172)
     11.1 INTRODUCTION 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 27 MICE MODEL MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
     11.3 REVENUE SHARE ANALYSIS (TOP 4 PLAYERS) 
             FIGURE 28 REVENUE ANALYSIS FOR TOP 4 COMPANIES (2020−2022)
             FIGURE 29 MARKET: MARKET SHARE ANALYSIS OF TOP 4 PLAYERS (2022)
     11.4 COMPANY EVALUATION QUADRANT FOR GLOBAL PLAYERS 
             11.4.1 STARS
             11.4.2 EMERGING LEADERS
             11.4.3 PERVASIVE PLAYERS
             11.4.4 PARTICIPANTS
                      FIGURE 30 MARKET: COMPANY EVALUATION MATRIX FOR GLOBAL PLAYERS (2022)
     11.5 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES 
             11.5.1 PROGRESSIVE COMPANIES
             11.5.2 STARTING BLOCKS
             11.5.3 RESPONSIVE COMPANIES
             11.5.4 DYNAMIC COMPANIES
                        FIGURE 31 MARKET: STARTUPS/SMES EVALUATION QUADRANT (2022)
             11.5.5 COMPETITIVE BENCHMARKING
                        11.5.5.1 Market: List of Startups/SMEs
                                      TABLE 208 MARKET: DETAILED LIST OF STARTUPS/SMES
                        11.5.5.2 Market: Competitive Benchmarking Of Key Players (Startups/SMEs)
                                      TABLE 209 MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (STARTUPS/SMES)
     11.6 COMPETITIVE SCENARIO AND TRENDS 
             11.6.1 PRODUCT LAUNCHES
                        TABLE 210 MARKET: PRODUCT LAUNCHES
             11.6.2 DEALS
                        TABLE 211 MARKET: DEALS
             11.6.3 OTHER DEVELOPMENTS
                        TABLE 212 MARKET: OTHER DEVELOPMENTS
 
12 COMPANY PROFILES (Page No. - 185)
     12.1 KEY PLAYERS 
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             12.1.1 CHARLES RIVER LABORATORIES
                        TABLE 213 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
                        FIGURE 32 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)
             12.1.2 THE JACKSON LABORATORY
                        TABLE 214 THE JACKSON LABORATORY: COMPANY OVERVIEW
                        FIGURE 33 THE JACKSON LABORATORY: COMPANY SNAPSHOT
             12.1.3 INOTIV
                        TABLE 215 INOTIV: COMPANY OVERVIEW
                        FIGURE 34 INOTIV: COMPANY SNAPSHOT
             12.1.4 GENOWAY
                        TABLE 216 GENOWAY: COMPANY OVERVIEW
                        FIGURE 35 GENOWAY: COMPANY SNAPSHOT (2022)
             12.1.5 TACONIC BIOSCIENCES, INC.
                        TABLE 217 TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW
             12.1.6 JANVIER LABS
                        TABLE 218 JANVIER LABS: COMPANY OVERVIEW
             12.1.7 HARBOUR BIOMED
                        TABLE 219 HARBOUR BIOMED: BUSINESS OVERVIEW
                        FIGURE 36 HARBOUR BIOMED: COMPANY SNAPSHOT (2021)
             12.1.8 TRANS GENIC INC.
                        TABLE 220 TRANS GENIC INC.: COMPANY OVERVIEW
                        FIGURE 37 TRANS GENIC INC.: COMPANY SNAPSHOT (2021)
             12.1.9 INGENIOUS TARGETING LABORATORY
                        TABLE 221 INGENIOUS TARGETING LABORATORY: COMPANY OVERVIEW
             12.1.10 POLYGENE
                        TABLE 222 POLYGENE AG: COMPANY OVERVIEW
             12.1.11 ARAGEN LIFE SCIENCES LTD.
                        TABLE 223 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW
             12.1.12 CYAGEN BIOSCIENCES
                        TABLE 224 CYAGEN BIOSCIENCES: COMPANY OVERVIEW
             12.1.13 CROWN BIOSCIENCE
                        TABLE 225 CROWN BIOSCIENCE: BUSINESS OVERVIEW
             12.1.14 TRANSCURE BIOSERVICES
                        TABLE 226 TRANSCURE BIOSERVICES: COMPANY OVERVIEW
             12.1.15 OZGENE PTY LTD.
                        TABLE 227 OZGENE PTY LTD.: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     12.2 OTHER PLAYERS 
             12.2.1 THE ANDERSONS, INC.
             12.2.2 ALLENTOWN, LLC
             12.2.3 INNOVIVE
             12.2.4 LAB PRODUCTS, LLC.
             12.2.5 CRESCENDO BIOLOGICS
             12.2.6 IMMUNOGENES
             12.2.7 LEXICON PHARMACEUTICALS, INC.
             12.2.8 HORIZON DISCOVERY LTD.
             12.2.9 MARSHALL BIORESOURCES
             12.2.10 APPLIED STEMCELL
 
13 APPENDIX (Page No. - 229)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the mice model market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the mice model market. The secondary sources used for this study include some of the key secondary sources referred to for this study include publications from government sources such as International Mouse Phenotyping Consortium (IMPC), Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), European Molecular Biology Laboratory - European Bioinformatics Institute (EMBL-EBI), Swiss Laboratory Animal Science Association (SGV), Medical Research Council (MRC), Asian Mouse Mutagenesis Resource Association (AMMRA), Annual Reports, Press Releases, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Mice Model Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME

DESIGNATION

Khaleel Ahmed

Business Development Executive

Adriano Flora

Director of Business Development

Hendrick Claeys

Sales Director

David Edgar

Business Development Executive

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the mice model market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the mice model business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Market: Bottom Up Approach

Mice Model Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Market Size: Top Down Approach

Mice Model Market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Mice models are the representation of human diseases or syndromes in mice, which are the most popular mammalian models for the study of human disease and health. Mice share more than 95% of the human DNA and are biologically very similar to humans. They can get many of the same diseases as humans for the same genetic reasons.

Key Stakeholders

  • Manufacturers and distributors of mice model products
  • Pharmaceutical and biotechnology companies
  • Market research and consulting firms
  • R&D centers
  • Researchers and scientists
  • Academic & research institutes

Report Objectives

  • To define, describe, and forecast the mice model market based on model types & services, technologies, application, and end user.
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, opportunities, and trends)
  • To strategically analyse micro markets with respect to individual growth trends, future prospects, and contributions to the overall mice model market
  • To analyse opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the mice model market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • Twenty five company profiles

Regional Analysis

  • Breakdown of RoW into Latin America and Middle East & Africa
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 2192
Published ON
Apr, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Mice Model Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback